de Gage SB, Bertrand M, Grimaldi S, et al. - Utilizing the French National Health Insurance Databases, researchers performed this observational study to describe the sociodemographic, medical and management characteristics of patients using intravitreal (IVT) anti-vascular endothelial growth factors (VEGF) in France. In total, 224,775 current users of IVT anti-VEGF in 2018 (mean age 78.1 ± 11.3 years, 60% female) and 330,969 new users between 2014 and 2018 (mean age 75.9 ± 12.0 years, 59% female) were involved. The characteristics of patients treated with IVT anti-VEGF and patterns of use in real-world conditions in France are reflected in this study, which was conducted at the scale of the entire French population. Less frequent dispensations and surveillance examinations were observed than in monthly schemes used in IVT anti-VEGF registration trials. Such findings could point to a lack of systematic monitoring associated with fewer injections, as well as clinicians' preference for more flexible and personalized injection schemes than those originally recommended.